Navigation Links
Antibiotic Ketek found to cause Liver damage

Drug Ketek is an antibiotic used to treat respiratory tract problems such as pneumonia, bronchitis and other lung infections//. Three patients taking the drug was reported to develop jaundice and liver problems following Ketek.

The three cases of ketek adverse effects as been reported in the Annals of Internal Medicine. The three patients did not have any liver problems with other drug prescriptions but after taking Ketek developed jaundice and abnormal liver function test (AST, ALT) and one of the three patients died.

Following the complications of Ketek, the FDA as advised the patients taking ketek if they develop any symptoms of jaundice or abnormal liver function test levels to stop taking the drugs immediately.
'"/>




Page: 1

Related medicine news :

1. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
2. Antibiotics Helps Autism
3. Antibiotics losing their power against acne
4. Antibiotic induces liver damage in children with E.COLI infections.
5. Antibiotics help heart patients
6. Antibiotics May Help Prevent Strokes
7. ICU Survival can be improved by Antibiotic use
8. Antibiotics Found To Increase The Risk Of Developing Breast Cancer
9. Antibiotics Overload For Kids Questioned
10. The Use Of Antibiotics Questioned
11. The Dangers Of Prescribing Antibiotics
Post Your Comments:
(Date:10/13/2008)...hkosh is one of six sites included in national stu...t survival rates, OSHKOSH, Wis., Oct. 13 /PRNewsw...//www.advancedcirculatory.com ) announced today th...unding from the National Institutes,of Health (NIH...combination,on those who experience cardiac arrest...
(Date:10/13/2008)...ine Exercises to Build and Maintain a Healthy Spin...fort to educate people,about spine health, Texas B...lease of these nine easy exercises coincides with ...ional Spine Health Day was established to bring at... most effective means of reducing the,prevalence a...
(Date:10/13/2008)... CoreValve ( www.corevalve.com ) annou...f its ReValving System for percutaneous aortic val...ortic stenosis continues to enroll patients at an ...ow been treated worldwide at nearly 100 centers in... Calif. (Business Wire EON) October 13, 2008 -- D...
(Date:10/13/2008)... is a significant problem in daily life, survey sh...re/ -- Approximately,three-quarters of people livi... problem in daily life, according to a National Ps...he survey of 426 individuals with psoriasis and ps... influences their daily lives, shapes their,feelin...
Breaking Medicine News(10 mins):Health News:Advanced Circulatory Systems Receives $1.5 Million From NIH for Study of Cardiac Arrest Resuscitation Techniques 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 3Health News: CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) : Highly encouraging registry data also presented at TCT 2008 2Health News:National Psoriasis Foundation Releases 2008 Study Results 2
...ories Limited has recently launched its approved g...elease tablets in the US, according to a press rel...anufacture and market Clarithromycin tablets—250 m...ycin tablets are indicated for the treatment of mi...
...ed by University of California-San Francisco has p... ephedra and guarana changes the cardiovascular sy...sure. It also has negative influence on glucose an...arheaded by Dr. Christine A. Haller and colleagues...
...e identified the single mutation of the gene invol...yndrome or primary erythromelalgia. Investigators ...r research findings that the single mutation of th...sponsible for people to suffer from the chronic co...
... shown that smoking during pregnancy is associated...an reverse this. Smoking during pregnancy is assoc...resent study had evaluated the relation between ma... monoxide (CO) concentrations (EACO) on the growth...
Other Medicine News:
(Date:10/13/2008)...ion of Genomic DNA from Multiple Cancer Population...tudies, ANN ARBOR, Mich., Oct. 13 /-...nt with SAIC-Frederick to amplify DNA samples for ...s was selected to amplify and standardize total ge... cancer patients. The Rubicon,GenomePlex(TM) Whole...
(Date:10/12/2008)... siRNAs Examined Alone and in Combination with Che...- Quark Pharmaceuticals, Inc., a,development-stage... novel,RNA interference (RNAi)-based therapeutics,...published results on efficacy of siRNA targeting,i...lung cancer (NSCLC) in,the edition dated October 1...
(Date:10/12/2008)...K, Mass. and WASHINGTON, Oct. 12 /PRNewswire-First... ) today announced results from an analysis,of nea...egistries, which,are designed to confirm the perfo...ting Coronary Stent System in real-world practice....AXUS Stent reduced clinical,restenosis in patients...
(Date:10/10/2008)...Z CREEK, Mich., Oct. 10 /- Diplomat S...cience has selected Diplomat,Specialty Pharmacy to...rge,scale, national Therapy Optimization Study for...wo year TOP MS study, is to examine the benefits o...on compliance, adherence and,patient outcomes. Tar...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Rice scientists make breakthrough in single molecule sensing 2138 1Rice scientists make breakthrough in single molecule sensing 2138 2Genesee 26 Wyoming Board Member Should Use Sarbanes Oxley Disclosure Rules in Non Profit Role Asserts 1199 SEIU 11155 1Genesee 26 Wyoming Board Member Should Use Sarbanes Oxley Disclosure Rules in Non Profit Role Asserts 1199 SEIU 11155 2Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System 1330 1Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System 1330 2Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System 1330 3Charles River Laboratories International Board Member Should Use Sarbanes Oxley Disclosure Rules in Non Profit Role Asserts 1199 SEIU 11147 1Charles River Laboratories International Board Member Should Use Sarbanes Oxley Disclosure Rules in Non Profit Role Asserts 1199 SEIU 11147 2
...mp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 200...l company focused on,the discovery and development...ced encouraging preclinical data of AV-412, a nove...of EGFR/HER2 using,AVEO,s unique EGFR mutant and d...s from the preclinical study showed that AV-412,is...
...ation on April 17, 2007 at AACR, SAN DIEGO, April ...s, Inc. presented data from an in vitro study show...natural killer (NK),cell-mediated anti-tumor respo...umor cells and enhanced antibody-dependent cellula...n at the Annual,Meeting of the American Associatio...
Other Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 2Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 3Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 4
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: